Of the many plants used by the pharmaceutical industry, cannabis is perhaps the only major one grown indoors. This provides extra security and enables GW Pharma to repeatedly grow batches of phytopharmaceutical feedstock of the high quality needed to produce a botanical drug like Sativex®. This multicomponent medicine contains a range of secondary metabolites, including the cannabinoids. By growing the plants in optimized uniform conditions, as outlined here, a consistent ratio of ingredients can be achieved. This chapter describes the morphology of the cannabis plant with specific emphasis on the trichomes, which produce the pharmaceutically important secondary metabolites. The possible natural function of these trichomes is debated. The growth of the plant in a natural outdoor setting, and in an indoor controlled environment, is compared, and newly emerging autoflowering plants described. The effect of contrasting growing conditions on plant morphology and secondary metabolite content is discussed.
Oxford Scholarship Online requires a subscription or purchase to access the full text of books within the service. Public users can however freely search the site and view the abstracts and keywords for each book and chapter.
If you think you should have access to this title, please contact your librarian.